PRAME [EPR20330]
As July marks Sarcoma/Bone Cancer Awareness Month, it is essential to highlight the key markers in clinical and research settings that contribute to our understanding of these diseases. Biocare Medical is a leading supplier known for its high-quality IHC reagents and solutions, including the PRAME EPR20330 antibody.
PRAME is located on chromosome 22q11.22 and encodes a 509 amino acid protein. PRAME is an autosomal cancer-testis antigen (CTA) gene which has been shown to be expressed in melanoma, various nonmelanocytic malignant neoplasms, including non-small cell lung cancer, breast carcinoma, renal cell carcinoma, ovarian carcinoma, leukaemia, synovial sarcoma, and myxoid liposarcoma. Normal healthy tissues are not known to express PRAME except for testis, ovary, adrenals, and endometrium.
PRAME (Preferentially Expressed Antigen in Melanoma) is a cancer-testis antigen that has gained significant attention for its diagnostic utility in immunohistochemistry (IHC) diagnostics. Here’s an overview of its diagnostic utility:
While generally used in melanoma differentiation and prognostics, PRAME also has utility in germ cell tumours, and its detection can aid in the diagnosis and characterization of tumours in Sarcomas.
Furthermore, PRAME is expressed in a variety of other cancers, including breast, lung, and ovarian cancers. While its expression in these cancers is not as specific as in melanoma, it can still provide useful diagnostic information, particularly in the context of poorly differentiated or undifferentiated tumours. BioCare Medical’s commitment to providing high-quality diagnostic tools ensures that their PRAME EPR20330 antibody is a reliable choice for pathology labs and researchers.
To find out more about PRAME [EPR20330], contact us below.
Get In Touch
